Don Soland
Direktor/Vorstandsmitglied bei DBV TECHNOLOGIES
Vermögen: 493 695 $ am 31.07.2023
Profil
Daniel B.
Soland is an Independent Director at ACADIA Pharmaceuticals, Inc. and DBV Technologies SA. He previously served as the President & Chief Executive Officer at Epigenesis Pharmaceuticals LLC from 2002 to 2005, the Chief Executive Officer & Executive Director at uniQure NV in 2016, the Director-Worldwide Marketing Operations & VP at Corixa Corp.
from 1993 to 2002, a Non-Executive Director at Oxford Biomedica Plc from 2015 to 2016, a Director at Tarsa Therapeutics, Inc., an Independent Director at KalVista Pharmaceuticals, Inc. from 2019 to 2022, the President-Chiron Vaccines at Chiron Corp.
from 2005 to 2006, the Chief Operating Officer & Senior Vice President at Shire ViroPharma, Inc. from 2008 to 2014, the President at Seqirus Vaccines Ltd.
in 2006, and the Chief Operating Officer & Senior Vice President at Viropharma, Inc. from 2008 to 2014.
He obtained his undergraduate degree from the University of Iowa.
Mr. Soland's current job(s) include being an Independent Director at ACADIA Pharmaceuticals, Inc. and DBV Technologies SA.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 01.06.2023 | 28 002 ( 0,02% ) | 456 713 $ | 30.04.2024 | |
DBV TECHNOLOGIES SA
0,03% | 29.02.2024 | 25 000 ( 0,03% ) | 33 254 $ | 30.04.2024 |
ACERAGEN, INC.
0,06% | 19.07.2023 | 4 637 ( 0,06% ) | 3 728 $ | 31.07.2023 |
Aktive Positionen von Don Soland
| Unternehmen | Position | Beginn |
|---|---|---|
| DBV TECHNOLOGIES | Direktor/Vorstandsmitglied | 06.03.2015 |
| ACADIA PHARMACEUTICALS INC. | Direktor/Vorstandsmitglied | 26.03.2015 |
Ehemalige bekannte Positionen von Don Soland
| Unternehmen | Position | Ende |
|---|---|---|
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Geschäftsführer | 28.09.2022 |
| KALVISTA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 26.05.2022 |
| UNIQURE N.V. | Vorstandsvorsitzender | 22.09.2016 |
| OXFORD BIOMEDICA PLC | Direktor/Vorstandsmitglied | 05.01.2016 |
| Viropharma, Inc. | Geschäftsführer | 01.12.2014 |
Ausbildung von Don Soland
| University of Iowa | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| ACADIA PHARMACEUTICALS INC. | Health Technology |
| OXFORD BIOMEDICA PLC | Health Technology |
| DBV TECHNOLOGIES | Health Technology |
| UNIQURE N.V. | Health Technology |
| KALVISTA PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Health Technology |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
Shire ViroPharma, Inc.
 Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Health Technology |
Corixa Corp.
 Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | Health Technology |
Seqirus Vaccines Ltd.
 Seqirus Vaccines Ltd. BiotechnologyHealth Technology Seqirus Vaccines Ltd. manufactures vaccines. The company is headquartered in Maidenhead, the United Kingdom. | Health Technology |
Epigenesis Pharmaceuticals LLC
 Epigenesis Pharmaceuticals LLC Pharmaceuticals: OtherHealth Technology Epigenesis Pharmaceuticals LLC develops inhaled respiratory medicines. It also provides treatments for the asthma, obstructive pulmonary disease and other respiratory diseases. The company was founded by Jonathan W. Nyce in 1995 and is headquartered in Cranbury, NJ. | Health Technology |
Tarsa Therapeutics, Inc.
 Tarsa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tarsa Therapeutics, Inc. engages in the development of therapies for the treatment and prevention of osteoporosis and related bone diseases. Its product OSTORA, is an oral formulation of calcitonin, which is a recombinant peptide hormone that inhibits bone resorption. The company was founded by David Brand and James Gilligan in 2009 and is headquartered in Philadelphia, PA. | Health Technology |
| Viropharma, Inc. |
